KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Petmed Express (PETS) Liabilities and Shareholders Equity (2016 - 2025)

Petmed Express' Liabilities and Shareholders Equity history spans 15 years, with the latest figure at $88.0 million for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity fell 39.25% year-over-year to $88.0 million; the TTM value through Dec 2025 reached $446.8 million, down 27.16%, while the annual FY2025 figure was $148.7 million, 12.47% down from the prior year.
  • Liabilities and Shareholders Equity reached $88.0 million in Q4 2025 per PETS's latest filing, down from $100.3 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $187.5 million in Q1 2021 to a low of $88.0 million in Q4 2025.
  • Average Liabilities and Shareholders Equity over 5 years is $156.0 million, with a median of $166.1 million recorded in 2022.
  • Peak YoY movement for Liabilities and Shareholders Equity: increased 20.71% in 2021, then crashed 39.25% in 2025.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $168.4 million in 2021, then rose by 0.7% to $169.6 million in 2022, then increased by 2.2% to $173.4 million in 2023, then decreased by 16.47% to $144.8 million in 2024, then plummeted by 39.25% to $88.0 million in 2025.
  • Per Business Quant, the three most recent readings for PETS's Liabilities and Shareholders Equity are $88.0 million (Q4 2025), $100.3 million (Q3 2025), and $109.8 million (Q2 2025).